Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial

Hao Su,1,* Xiao Shang,1,* Hongruo Liu,2 Yutong Wang,1 Yang Yu,3 Yanhua Xu,4 Kui Jiang,2,* Fengzhi Feng1,* 1Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetric & Gynecologic Diseases, Peking Union Medical College Hospital, Chine...

Full description

Saved in:
Bibliographic Details
Main Authors: Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, Feng F
Format: Article
Language:English
Published: Dove Medical Press 2025-02-01
Series:International Journal of Women's Health
Subjects:
ovarian cancer
platinum-resistant
immune checkpoint inhibitor
lenvatinib
dose adjustment
Online Access:https://www.dovepress.com/efficacy-and-safety-of-low-dose-lenvatinib-and-toripalimab-in-patients-peer-reviewed-fulltext-article-IJWH
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.dovepress.com/efficacy-and-safety-of-low-dose-lenvatinib-and-toripalimab-in-patients-peer-reviewed-fulltext-article-IJWH

Similar Items